New Anti Epileptic drug launched in the US market by Dr Reddy’s

launch-spelled-out-by-cubes_large

Dr. Reddy’s Laboratories Ltd. announced that it has launched the antiepileptic drug, Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation’s Levetiracetam in Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

As per Dr Reddy’s Laboratories, the Levetiracetam in Sodium Chloride Injection brand and generic had U.S. sales of approximately $37 million MAT for the most recent twelve months ending in April 2018.

Dr. Reddy’s Levetiracetam in Sodium Chloride Injection is available in strengths of 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags.

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Epilepsy indication, visit https://pharmascroll.com/news-category/epilepsy/

 

News Source: Dr Reddy’s Laboratories website

Image Source: https://www.fool.com/investing/2018/01/21/this-marijuana-stock-just-might-have-1-of-the-bigg.aspx